Program Overview
Learning Objectives
Target Audience
References
Disclosure/Disclaimer
About this activity
References
Discussion Forum (0)
ISID “Leveraging Vaccines to Reduce Antibiotics Use and Prevent Antimicrobial Resistance” Webinar
This webinar was hosted on Sep 15, 2021, Wednesday 9:00 am – 10:00 am EDT
Moderators:
Marc Mendelson
Afreenish Amir
Speakers:
Anthony Fiore
Paul Tambyah
Antimicrobial resistance (AMR) is one of the biggest global health threats. Antibiotics are becoming increasingly ineffective as drug-resistance spreads leading to more difficult to treat infections. Fighting this threat is a public health priority that requires a collaborative global approach across sectors.
Controlling AMR demands improvements in infection prevention, antimicrobial stewardship, and antimicrobial discovery. A powerful measure to reduce the use of antimicrobials, and hence development of resistance, is to prevent the occurrence of infections. Vaccines can impact AMR in two ways. Vaccines can reduce or eliminate the risk of infection due to antibiotic-resistant strains, for example pneumococcal vaccine. Vaccines can also have a secondary effect on AMR by preventing antibiotic use by reducing the rates of viral febrile illness episodes and the likelihood of secondary bacterial infections following the prevented episode. Viral infections are a strong driver of use and misuse of antibiotics and vaccines are an impactful and effective public health measure for the prevention of many viral infections. Single or combination vaccines may ultimately result in synergistic effects on decreasing antimicrobial use and therefore resistance. In this way, vaccines targeting viral illnesses become a tool to reinforce policies of antibiotic stewardship.
WHO has developed a strategy to articulate the role of vaccines against AMR and an action framework that describes a vision for vaccines to contribute fully, sustainably and equitably to the prevention and control of antimicrobial resistance by preventing infections and reducing antimicrobial use. During this webinar, speakers will discuss how vaccines targeting viral illnesses contribute to the battle against AMR by preventing infections and by reducing antimicrobial use.
This webinar is supported by an unrestricted educational grant from Sanofi Pasteur.
Please take 2 min after the webinar to fill out our evaluation form: https://isid.typeform.com/to/vDqYDBPQ
This webinar was hosted on Sep 15, 2021, Wednesday 9:00 am – 10:00 am EDT
Moderators:
Marc Mendelson
Afreenish Amir
Speakers:
Anthony Fiore
Paul Tambyah
Antimicrobial resistance (AMR) is one of the biggest global health threats. Antibiotics are becoming increasingly ineffective as drug-resistance spreads leading to more difficult to treat infections. Fighting this threat is a public health priority that requires a collaborative global approach across sectors.
Controlling AMR demands improvements in infection prevention, antimicrobial stewardship, and antimicrobial discovery. A powerful measure to reduce the use of antimicrobials, and hence development of resistance, is to prevent the occurrence of infections. Vaccines can impact AMR in two ways. Vaccines can reduce or eliminate the risk of infection due to antibiotic-resistant strains, for example pneumococcal vaccine. Vaccines can also have a secondary effect on AMR by preventing antibiotic use by reducing the rates of viral febrile illness episodes and the likelihood of secondary bacterial infections following the prevented episode. Viral infections are a strong driver of use and misuse of antibiotics and vaccines are an impactful and effective public health measure for the prevention of many viral infections. Single or combination vaccines may ultimately result in synergistic effects on decreasing antimicrobial use and therefore resistance. In this way, vaccines targeting viral illnesses become a tool to reinforce policies of antibiotic stewardship.
WHO has developed a strategy to articulate the role of vaccines against AMR and an action framework that describes a vision for vaccines to contribute fully, sustainably and equitably to the prevention and control of antimicrobial resistance by preventing infections and reducing antimicrobial use. During this webinar, speakers will discuss how vaccines targeting viral illnesses contribute to the battle against AMR by preventing infections and by reducing antimicrobial use.
This webinar is supported by an unrestricted educational grant from Sanofi Pasteur.
Please take 2 min after the webinar to fill out our evaluation form: https://isid.typeform.com/to/vDqYDBPQ
- Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: An Action Framework and annex to Immunization Agenda 2030. World Health Organization, 2020. www.who.int/publications/m/item/leveraging-vaccines-to-reduce-antibiotic-use-and-prevent-antimicrobial-resistance
- Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects. Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12896-12901. doi: 10.1073/pnas.1721095115. https://pubmed.ncbi.nlm.nih.gov/30559195/
- Vaccines for AMR. Report commissioned by Wellcome Trust, "Vaccines to tackle drug resistant infections: An evaluation of R&D opportunities". https://amr.solutions/2018/10/09/vaccines-for-amr-a-major-review-of-rd-opportunities/
- World Health Organization (WHO). Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries. A WHO practial toolkit. 2019. https://www.who.int/publications/i/item/9789241515481
- World Health Organization (WHO). Immunisation Agenda 2030: A Global Strategy to Leave No One Behind. 2020. https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/ia2030
Leveraging Vaccines to Reduce Antibiotics Use and Prevent Antimicrobial Resistance (open-access)
Marc Mendelson
Afreenish Amir
Anthony Fiore
Paul Tambyah
About this activity
References
Discussion Forum (0)
ISID “Leveraging Vaccines to Reduce Antibiotics Use and Prevent Antimicrobial Resistance” Webinar
This webinar was hosted on Sep 15, 2021, Wednesday 9:00 am – 10:00 am EDT
Moderators:
Marc Mendelson
Afreenish Amir
Speakers:
Anthony Fiore
Paul Tambyah
Antimicrobial resistance (AMR) is one of the biggest global health threats. Antibiotics are becoming increasingly ineffective as drug-resistance spreads leading to more difficult to treat infections. Fighting this threat is a public health priority that requires a collaborative global approach across sectors.
Controlling AMR demands improvements in infection prevention, antimicrobial stewardship, and antimicrobial discovery. A powerful measure to reduce the use of antimicrobials, and hence development of resistance, is to prevent the occurrence of infections. Vaccines can impact AMR in two ways. Vaccines can reduce or eliminate the risk of infection due to antibiotic-resistant strains, for example pneumococcal vaccine. Vaccines can also have a secondary effect on AMR by preventing antibiotic use by reducing the rates of viral febrile illness episodes and the likelihood of secondary bacterial infections following the prevented episode. Viral infections are a strong driver of use and misuse of antibiotics and vaccines are an impactful and effective public health measure for the prevention of many viral infections. Single or combination vaccines may ultimately result in synergistic effects on decreasing antimicrobial use and therefore resistance. In this way, vaccines targeting viral illnesses become a tool to reinforce policies of antibiotic stewardship.
WHO has developed a strategy to articulate the role of vaccines against AMR and an action framework that describes a vision for vaccines to contribute fully, sustainably and equitably to the prevention and control of antimicrobial resistance by preventing infections and reducing antimicrobial use. During this webinar, speakers will discuss how vaccines targeting viral illnesses contribute to the battle against AMR by preventing infections and by reducing antimicrobial use.
This webinar is supported by an unrestricted educational grant from Sanofi Pasteur.
Please take 2 min after the webinar to fill out our evaluation form: https://isid.typeform.com/to/vDqYDBPQ
This webinar was hosted on Sep 15, 2021, Wednesday 9:00 am – 10:00 am EDT
Moderators:
Marc Mendelson
Afreenish Amir
Speakers:
Anthony Fiore
Paul Tambyah
Antimicrobial resistance (AMR) is one of the biggest global health threats. Antibiotics are becoming increasingly ineffective as drug-resistance spreads leading to more difficult to treat infections. Fighting this threat is a public health priority that requires a collaborative global approach across sectors.
Controlling AMR demands improvements in infection prevention, antimicrobial stewardship, and antimicrobial discovery. A powerful measure to reduce the use of antimicrobials, and hence development of resistance, is to prevent the occurrence of infections. Vaccines can impact AMR in two ways. Vaccines can reduce or eliminate the risk of infection due to antibiotic-resistant strains, for example pneumococcal vaccine. Vaccines can also have a secondary effect on AMR by preventing antibiotic use by reducing the rates of viral febrile illness episodes and the likelihood of secondary bacterial infections following the prevented episode. Viral infections are a strong driver of use and misuse of antibiotics and vaccines are an impactful and effective public health measure for the prevention of many viral infections. Single or combination vaccines may ultimately result in synergistic effects on decreasing antimicrobial use and therefore resistance. In this way, vaccines targeting viral illnesses become a tool to reinforce policies of antibiotic stewardship.
WHO has developed a strategy to articulate the role of vaccines against AMR and an action framework that describes a vision for vaccines to contribute fully, sustainably and equitably to the prevention and control of antimicrobial resistance by preventing infections and reducing antimicrobial use. During this webinar, speakers will discuss how vaccines targeting viral illnesses contribute to the battle against AMR by preventing infections and by reducing antimicrobial use.
This webinar is supported by an unrestricted educational grant from Sanofi Pasteur.
Please take 2 min after the webinar to fill out our evaluation form: https://isid.typeform.com/to/vDqYDBPQ
- Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: An Action Framework and annex to Immunization Agenda 2030. World Health Organization, 2020. www.who.int/publications/m/item/leveraging-vaccines-to-reduce-antibiotic-use-and-prevent-antimicrobial-resistance
- Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects. Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12896-12901. doi: 10.1073/pnas.1721095115. https://pubmed.ncbi.nlm.nih.gov/30559195/
- Vaccines for AMR. Report commissioned by Wellcome Trust, "Vaccines to tackle drug resistant infections: An evaluation of R&D opportunities". https://amr.solutions/2018/10/09/vaccines-for-amr-a-major-review-of-rd-opportunities/
- World Health Organization (WHO). Antimicrobial stewardship programmes in health-care facilities in low- and middle-income countries. A WHO practial toolkit. 2019. https://www.who.int/publications/i/item/9789241515481
- World Health Organization (WHO). Immunisation Agenda 2030: A Global Strategy to Leave No One Behind. 2020. https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/ia2030
{{ help_message }}
{{filter}}